Antibody Therapeutics Xchange
Europe 2022
Zurich, November 22

Welcome to hubXchange’s Europe Antibody Therapeutics Xchange 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 – 8152 Opfikon, Switzerland

Target Selection

Titles and Bullets
8:00 – 8:30am
8:30 – 9:00am

Opening Address & Keynote

9:05 – 10:05am

Considerations and challenges guiding target selection in the development of antibody-based therapeutics


10:10 – 10:40am
1-2-1 Meetings/Networking Break
10:40 – 11:10am
1-2-1 Meetings/Networking Break
11:10 – 11:20am
Morning Refreshment Break
11:20am – 12:20pm

Synexa roundtable TBC

12:20 – 1:20pm
Networking Lunch
1:20 – 1:50pm

ImmunoPrecise Antibodies Keynote Presentaion

1:55 – 2:55pm
Antibody target selection challenges: splicing, multimeric complexes, and glycosylation
3:00 – 3:30pm
1-2-1 Meetings/Networking Break
3:30 – 4:00pm
1-2-1 Meetings/Networking Break
4:00 – 4:10pm
Afternoon Refreshments
4:10 – 4:40pm
Poster Session: BioRad
4:45– 5:45pm

How to gain the full potential out of the emerging pipeline of cancer therapies

Sr Director, Portfolio Management, Symphogen

Johan Lantto is a Sr Director, Portfolio Management at Symphogen, a Servier company based in Denmark. Johan holds a Ph.D. in Immunotechnology from Lund University, Sweden, where he studied antibody evolution and repertoire development, and he has more than 20 years of experience with antibody engineering and the development of therapeutic antibodies. For the past 18 years, Johan has worked for Symphogen where he has been involved in the development of the company’s Symplex™ antibody discovery platform as well as been responsible for antibody drug discovery and development projects within infectious disease and oncology. Johan has been responsible for six oncology projects that have been brought to the clinic by Symphogen.

Portrait picture of Johan Lantto
5:45– 6:45pm
Canape/Drinks Reception


Antibody Therapeutics Xchange | Europe 2022